---
title: Canine Cancer Osteosarcoma Research
description: Canine osteosarcoma research
image: https://blog.fidocure.com/hubfs/Identification%20of%20genomic%20alterations%20with%20clinical%20impact%20in%20canine%20splenic%20hemangiosarcoma%20(6).png
---
[](https://www.fidocure.com/)
- [Veterinarians](https://fidocure.com/for-veterinarians/)
- [Portal Login](https://dvm.fidocure.com/)
- [Veterinary Blog](https://blog.fidocure.com/fidocure-blog/tag/vet)
- [Case Studies](https://blog.fidocure.com/fidocure-blog/tag/case-studies)
- [Webinars](https://blog.fidocure.com/fidocure-blog/tag/webinars)
- [Pet Parents](https://fidocure.com/pet-parents/)
- [About Us](https://fidocure.com/about-us/)
- [How it works](https://fidocure.com/how-it-works/)
- [Find a Clinic](https://fidocure.com/find-a-clinic/)
- [Contact Us](https://fidocure.com/contact-us/)
[Vet](https://blog.fidocure.com/fidocure-blog/tag/vet)
# Canine Cancer Osteosarcoma Research
[Dr. Lucas Rodrigues](https://blog.fidocure.com/fidocure-blog/author/dr-lucas-rodrigues)
[Share this blog post on Twitter](https://twitter.com/intent/tweet?text=I+found+this+interesting+blog+post&url=https://blog.fidocure.com/fidocure-blog/canine-cancer-osteosarcoma-research) [Share this blog post on Facebook](http://www.facebook.com/share.php?u=https://blog.fidocure.com/fidocure-blog/canine-cancer-osteosarcoma-research) [Share this blog post on LinkedIn](http://www.linkedin.com/shareArticle?mini=true&url=https://blog.fidocure.com/fidocure-blog/canine-cancer-osteosarcoma-research)
In our relentless pursuit of advancements in veterinary oncology, the FidoCure Team's research has taken center stage, offering an in-depth exploration into the realm of canine osteosarcoma. The use of real-world data and machine learning techniques promises to provide invaluable insights into the mutation patterns and treatment outcomes associated with this challenging condition.
### KEY FINDINGS
1. **Identification of Prognostic Genomic Alterations**: This research delves into the genomic landscape of dogs with osteosarcoma to identify key genetic mutations. The study reveals that *KDR* and *KMT2D* mutations serve as prognostic markers for poor survival, shedding light on the underlying genetics of this aggressive tumor.
2. **Improved Survival with Targeted Therapy**: The study demonstrates a significant increase in median survival time for dogs with *TP53* mutations when treated with vorinostat, an HDAC inhibitor. The findings underscore the potential of targeted therapy in enhancing survival outcomes, offering new hope for osteosarcoma patients with *TP53* mutations.
3. **Accelerating Translational Cancer Research**: By confirming these associations with the FidoCure® database, this research paves the way for accelerated clinical studies and the development of novel treatments, not only benefiting dogs with osteosarcoma but also holding promise for advancements in human cancer research.
We believe that these findings are not only pertinent to our community of veterinarians and researchers but also hold the potential to impact the lives of our beloved patients who face this daunting diagnosis.
## Related Articles
[.png)](https://blog.fidocure.com/fidocure-blog/unlocking-precision-oncology-insights-from-top-articles-canine-cancer-studies)
### [Unlocking Precision Oncology: Insights from Top Articles & Canine Cancer Studies](https://blog.fidocure.com/fidocure-blog/unlocking-precision-oncology-insights-from-top-articles-canine-cancer-studies)
Precision medicine revolutionizes cancer care by tailoring treatments to each patient's tumor, but major roadblocks remain. These top articles dive into the key...
[FidoCure](https://blog.fidocure.com/fidocure-blog/author/fidocure)
[Read More](https://blog.fidocure.com/fidocure-blog/unlocking-precision-oncology-insights-from-top-articles-canine-cancer-studies)
[](https://blog.fidocure.com/fidocure-blog/data-first-pet-healthcare-how-fidocure-is-leveraging-big-data-to-improve-canine-cancer-outcomes)
### [Data-First Pet Healthcare: How FidoCure is Leveraging Big Data to Improve Canine Cancer Outcomes](https://blog.fidocure.com/fidocure-blog/data-first-pet-healthcare-how-fidocure-is-leveraging-big-data-to-improve-canine-cancer-outcomes)
In the fight against canine cancer, one of the most powerful tools at medicine’s disposal is data. Data can help describe genomes, uncover patterns in care and outcomes,...
[FidoCure](https://blog.fidocure.com/fidocure-blog/author/fidocure)
[Read More](https://blog.fidocure.com/fidocure-blog/data-first-pet-healthcare-how-fidocure-is-leveraging-big-data-to-improve-canine-cancer-outcomes)
- [How it Works](https://fidocure.com/how-it-works/)
- [FAQ](https://fidocure.com/faq/)
- [Contact Us](https://fidocurestg.wpengine.com/contact-us/)
- [For Vets](https://fidocure.com/for-veterinarians/)
- [About Us](https://fidocure.com/about-us/)
- [Terms of Service](https://fidocure.com/terms-of-service/)
- [Blog](https://blog.fidocure.com/fidocure-blog)
- [Careers](https://fidocure.com/careers/)
- [Privacy Policy](https://fidocure.com/privacy-policy/)
-
-
-
-
**FidoCure® is an advanced cancer-care service for dogs, developed by One Health Company**. DISCLAIMER: All patients are enrolled in FidoCure® by a veterinarian with a valid veterinarian-client-patient relationship (VCPR). We use best efforts to inform the veterinarian on available targeted therapy options for patients. FidoCure® does not prescribe therapy. The targeted therapies that veterinarians may prescribe and order from compounding pharmacies, after receiving genetic test results from FidoCure®, may constitute extra-label uses of those drugs. FidoCure® makes no claims that every patient will have genetic test results that lead to targeted therapy options. FidoCure® makes no claims or guarantees about the effectiveness of the diagnostic and targeted therapy selected by the veterinarian for an individual patient. Like most cancer care approaches, the services provided by FidoCure® are not a guarantee of a cure. FidoCure® is not a pharmacy and does not supply drugs directly. By ordering any medication via one of our pharmacy partners, you agree that the pharmacy, not FidoCure®, is solely responsible and liable for any and all issues relating to the preparation, dispensation and fulfillment of the medication. The lifetime offer is subject to the commercially reasonable availability of any medication(s) and/or active pharmaceutical ingredient(s) necessary for the selected therapy.
© Copyright 2018-2026 One Health Company, All rights reserved
```json
{
"@context" : "https://schema.org",
"@type" : "BlogPosting",
"author" : {
"@type" : "Person",
"name" : "Dr. Lucas Rodrigues",
"url" : "https://blog.fidocure.com/fidocure-blog/author/dr-lucas-rodrigues"
},
"dateModified" : "2023-10-30T14:48:48.907Z",
"datePublished" : "2023-10-26T21:02:46.000Z",
"headline" : "Canine Cancer Osteosarcoma Research",
"image" : [ "https://blog.fidocure.com/hubfs/Identification%20of%20genomic%20alterations%20with%20clinical%20impact%20in%20canine%20splenic%20hemangiosarcoma%20(6).png" ],
"mainEntityOfPage" : {
"@id" : "https://blog.fidocure.com/fidocure-blog/canine-cancer-osteosarcoma-research",
"@type" : "WebPage"
},
"publisher" : {
"@type" : "Organization",
"logo" : {
"@type" : "ImageObject",
"url" : "https://blog.fidocure.com/hubfs/fidocure_logo.png"
},
"name" : "FidoCure"
}
}
```